Opinions
Jim Cramer - Mad Money
Doximity
DOX-N
BUY
Dec 06, 2021
He likes it and doctors really like its services. Expensive in terms of valuation, but is closer to a bottom than a week ago.
N/A
Stock price when the opinion was issued
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
BUY
Doximity is a new SPAC, a cloud-based social network for MDs offering cloud-based tools that let doctors perform everyday tasks. It's also the ideal platform for advertisers to pitch drugs to doctors. Share have been wild over the past four weeks, but is up 12% this week so far. Buy on pullback. Likes it for being the dominant platform for doctors, connecting over 80% of the nation's docs. It boasts high revenue growth at 78%, and profitability over years as margins expand going forward. They launched a telemedicine growth during last year's lockdown, so that will likely tail off. Net revenue retention rate was up 153% last year. Fabulous fundamentals. But overall, he fears the SPAC scene will collapse from too many of them and of low quality, and that could drag DOX down. Also, DOX's valuation is higher than peers, but that's compensated by a stronger growth profile. When they IPO'd, they offered only 13% of shares to the public, so beware of the end of the lock-up period--buy then. If now, buy a small position.
Healthcare